title: A novel pattern of transaminase elevation associated with autologous transplant for neuroblastoma.
abstract: To determine the pattern and degree of hepatic transaminitis experienced by children undergoing autologous transplantation for neuroblastoma. Sixty-four children with high-risk neuroblastoma received an autologous transplant with cyclophosphamide, etoposide, and carboplatin conditioning. Forty-eight went on to receive a second transplant with M and TBI conditioning. Charts were reviewed for evidence of hepatic regimen-related toxicity. A high rate of transaminitis was observed after both regimens. In each transplant, there was an early period of transaminitis during conditioning, from which patients recovered, followed by a second period of transaminase elevation. The degree of elevation was not associated with age, whether the administered dose was calculated based on a per kg or per M(2) basis or the presence of regimen-related severe mucositis. Elevated transaminases at admission were not associated with maximal hepatotoxicity during the first transplant although there was an association in the second transplant. However, the magnitude of transaminase elevation was less in the second transplant. VOD occurred in one and three patients in transplants 1 and 2, respectively. Both conditioning regimens were associated with an early and late elevation of transaminases without significant cholestasis. This biphasic pattern of transaminitis has not been reported previously. The high prevalence of transaminase elevation at time of both transplants was not associated with an increased incidence of VOD. We conclude that elevated transaminases should not preclude proceeding to a first or second autologous transplant with these regimens.
authors.affiliation: Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Pediatric Hematology/Oncology and the Clinical Research Program, Children's Hospital Boston, Boston, MA 02115, USA. eva-guinan@dfci.harvard.edu
authors.forename: Eva C
authors.initials: EC
authors.lastname: Guinan
authors.forename: Leslie A
authors.initials: LA
authors.lastname: Kalish
authors.forename: Winter S
authors.initials: WS
authors.lastname: Berry
authors.forename: Samuel
authors.initials: S
authors.lastname: McDaniel
authors.forename: Leslie E
authors.initials: LE
authors.lastname: Lehmann
authors.forename: Lisa R
authors.initials: LR
authors.lastname: Diller
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D016190:Carboplatin / Q000008:administration & dosage; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D009447:Neuroblastoma / Q000628:therapy*; D012189:Retrospective Studies; D012307:Risk Factors; D000637:Transaminases / Q000097:blood*; D019172:Transplantation Conditioning / Q000379:methods*; D014182:Transplantation, Autologous
chemical_list: D005047:Etoposide; D003520:Cyclophosphamide; D016190:Carboplatin; D000637:Transaminases